Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
07 5월 2024 - 2:57AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed
by the Registrant ☒ Filed by a Party other than the Registrant ☐
☐ |
Preliminary
Proxy Statement |
|
|
☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive
Proxy Statement |
|
|
☒ |
Definitive
Additional Materials |
|
|
☐ |
Soliciting
Material under §240.14a-12 |
Provectus
Biopharmaceuticals, Inc.
(Name
of registrant as specified in its charter)
(Name
of person(s) filing proxy statement, if other than the registrant)
Payment
of Filing Fee (Check the appropriate box):
☒ |
No
fee required |
|
|
☐ |
Fee
paid previously with preliminary materials. |
|
|
☐ |
Fee computed on table in exhibit required by Item 25(b)
per Exchange Act Rules 14a–6(i)(1) and 0–11 |
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Provectus Biopharmaceuticals Inc (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Provectus Biopharmaceuticals Inc (QB) News Articles